These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12173280)

  • 41. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
    Lazzaroni M; Bianchi Porro G
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
    Greene JM; Winickoff RN
    Arch Intern Med; 1992 Oct; 152(10):1995-2002. PubMed ID: 1417372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
    Bae SC; Corzillius M; Kuntz KM; Liang MH
    Rheumatology (Oxford); 2003 Jan; 42(1):46-53. PubMed ID: 12509612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.
    Becker JC; Domschke W; Pohle T
    Br J Clin Pharmacol; 2004 Dec; 58(6):587-600. PubMed ID: 15563357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.
    Lanas A; Ferrandez A
    Drugs Aging; 2007; 24(2):121-31. PubMed ID: 17313200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The risks and costs of upper gastrointestinal disease attributable to NSAIDs.
    Smalley WE; Griffin MR
    Gastroenterol Clin North Am; 1996 Jun; 25(2):373-96. PubMed ID: 9229579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Side effects cause enormous costs. Expensive arthritis therapy].
    MMW Fortschr Med; 2001 Nov; 143(46):60. PubMed ID: 11759607
    [No Abstract]   [Full Text] [Related]  

  • 53. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cost study of NSAID use in rheumatoid arthritis based on recent therapeutic protocols].
    Inotai A; Vincze Z
    Acta Pharm Hung; 2008; 78(2):79-86. PubMed ID: 18807388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
    Patino FG; Allison J; Olivieri J; Mudano A; Juarez L; Person S; Mikuls TR; Moreland L; Kovac SH; Saag KG
    Arthritis Rheum; 2003 Jun; 49(3):293-9. PubMed ID: 12794782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman A; Ellershaw J
    Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs.
    Pok LSL; Shabaruddin FH; Dahlui M; Sockalingam S; Mohamed Said MS; Rosman A; Lau IS; Isa LM; Hussein H; Ng CT; Mahadeva S
    Int J Rheum Dis; 2018 May; 21(5):943-951. PubMed ID: 29314744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost of treating arthritis and NSAID-related gastrointestinal side-effects.
    Bloom BS
    Aliment Pharmacol Ther; 1988; 2 Suppl 1():131-8. PubMed ID: 2979281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
    Spiegel BM; Farid M; Dulai GS; Gralnek IM; Kanwal F
    Am J Med; 2006 May; 119(5):448.e27-36. PubMed ID: 16651060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.